Labcorp Holdings, Inc. provides laboratory services to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

Labcorp Holdings Inc.

Labcorp to leverage Roche's digital pathology technology to expand access, enhance efficiency and support AI integration across anatomic pathology services BURLINGTON, N.C. , Sept. 30, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today a collaboration with Roche to implement the company's FDA-cleared VENTANA® DP 600 and DP 200 slide scanners.

Labcorp Announces Collaboration with Roche to Advance Digital Pathology Capabilities

BURLINGTON, N.C. , Sept. 25, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2025 before the market opens on Tuesday, October 28, 2025.

Labcorp to Announce Third Quarter Financial Results on October 28, 2025

Labcorp (LH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Labcorp Holdings Inc. (LH) Hit a 52 Week High, Can the Run Continue?

LH's biopharma lab growth and efficiency gains boost momentum, but currency and macro pressures weigh on its outlook.

Reasons to Add Labcorp Stock to Your Portfolio Right Now

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Labcorp Holdings (LH) is a Strong Value Stock

Labcorp's $225M acquisition of BioReference Health select assets boosts its oncology diagnostics portfolio and expands patient access nationwide.

LH Stock Rises on Acquisition of BioReference Health's Select Assets

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Labcorp Holdings (LH) is a Strong Growth Stock

Labcorp Holdings Inc. (NYSE:LH ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:45 AM EDT Company Participants Adam Schechter - President, CEO & Chairman Julia Wang - CFO & Executive VP Conference Call Participants Erin Wilson Wright - Morgan Stanley, Research Division Presentation Erin Wilson Wright Equity Analyst Good morning, everyone. I'm Erin Wright, health care services analyst at Morgan Stanley.

Labcorp Holdings Inc. (LH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Why Labcorp Holdings (LH) is a Top Value Stock for the Long-Term

BURLINGTON, N.C. , Aug. 27, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, Sept.

Labcorp to Speak at the Morgan Stanley 23rd Annual Global Healthcare Conference

LH witnesses growth in specialty testing and strategic acquisitions, but macro and currency headwinds remain a concern.

Is it the Right Time to Hold Labcorp Stock in Your Portfolio?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Labcorp Holdings (LH) is a Strong Momentum Stock

Why Labcorp Holdings (LH) is a Top Growth Stock for the Long-Term

LH launches the first FDA-cleared blood test for Alzheimer's, boosting access to early diagnosis and nudging its stock higher.

Labcorp Debuts First FDA-Cleared Blood Test for Alzheimer's, Stock Up

Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C. , Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first blood-based in-vitro diagnostic (IVD) test cleared by the U.S. Food and Drug Administration (FDA) to aid in the diagnosis of Alzheimer's disease through early detection of the amyloid plaques associated with the disease in appropriate patients.

Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease

Why Labcorp Holdings (LH) is a Top Momentum Stock for the Long-Term

Test Finder interprets provider questions in context to deliver curated, clinically relevant results, going beyond traditional search Developed in collaboration with Amazon Web Services, Test Finder is now available on Labcorp.com BURLINGTON, N.C. , July 30, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Test Finder, a first-of-its-kind generative AI tool developed with Amazon Web Services (AWS).

Labcorp Introduces Test Finder, a First-of-Its-Kind Generative AI Tool to Simplify Lab Test Search

First-and-only test of its kind approved under new European Union regulations expands access to personalized cancer care for patients across the EU BURLINGTON, N.C. , July 29, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today PGDx elio™ tissue complete has been CE-marked under the European Union's (EU) new In Vitro Diagnostic Regulation (IVDR).

Labcorp Achieves IVDR CE-Marking for PGDx elio™ tissue complete in the EU

Real-time stock quote and overview for LH